Sign in
TerminatedPhase 4

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Key facts

Who runs it
David Binion, MD
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 4
People taking part
19 people enrolled
Started
14 Oct 2021
Ended
31 May 2024
Type of study
Interventional
Treatments tested
  • Bezlotoxumab
Record updated
5 June 2025
Why it stopped
Sponsor's decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • >18 years old
  • active CDI receiving therapy
  • diagnosis of IBD
  • and history of CDI

Who cannot take part

  • history of colectomy
  • history of preexisting congestive heart failure
  • past cardiac history
  • <18 years old
  • no IBD
  • no CDI
  • pregnant or nursing women
  • TCP<50

Where in United States

  • University of Pittsburgh Medical CenterPittsburgh, United States

About the trial

What the trial wants to find out

The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.

The group in the trial

  • Open labelOther group

    Single arm

    Treatment: Bezlotoxumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 June 2025